Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010)

Bone

Volumn 73, Issue , 2015, Pages 1-7

  Griebeler, Marcio L ^a   Kearns, Ann E ^a   Ryu, Euijung ^a   Hathcock, Matthew A ^a   Melton, L Joseph ^a   Wermers, Robert A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Epidemiology; Hypercalcemia; Incidence; Osteoporosis; Primary hyperparathyroidism

Indexed keywords

CALCIUM; PARATHYROID HORMONE;

ADULT; AGE DISTRIBUTION; AGED; AGING; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; ENDOCRINE FUNCTION TEST; FEMALE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; MEDICARE; MIDDLE AGED; OSTEOPOROSIS; PARATHYROIDECTOMY; PRIMARY HYPERPARATHYROIDISM; TREND STUDY; UNITED STATES; COHORT ANALYSIS; HISTORY; HYPERPARATHYROIDISM, PRIMARY;

AGED; COHORT STUDIES; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; HYPERPARATHYROIDISM, PRIMARY; INCIDENCE; MALE; MIDDLE AGED; NEW YORK;

EID: 84919642249     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2014.12.003     Document Type: Article

References (34)

1. Melton L.J. The epidemiology of primary hyperparathyroidism in North America. J Bone Miner Res 2002, 17(Suppl. 2):N12-N17.
2. Fraser W.D. Hyperparathyroidism. Lancet 2009, 374:145-158.
3. Heath H., Hodgson S.F., Kennedy M.A. Primary hyperparathyroidism. Incidence, morbidity, and potential economic impact in a community. N Engl J Med 1980, 302:189-193.
4. Yu N., Donnan P.T., Murphy M.J., Leese G.P. Epidemiology of primary hyperparathyroidism in Tayside, Scotland, UK. Clin Endocrinol 2009, 71:485-493.
5. Abood A., Vestergaard P. Increasing incidence of primary hyperparathyroidism in Denmark. Dallas Med J 2013, 60:A4567.
6. Jorde R., Bonaa K.H., Sundsfjord J. Primary hyperparathyroidism detected in a health screening. The Tromso study. J Clin Epidemiol 2000, 53:1164-1169.
7. Wermers R.A., Khosla S., Atkinson E.J., Hodgson S.F., O'Fallon W.M., Melton L.J. The rise and fall of primary hyperparathyroidism: a population-based study in Rochester, Minnesota, 1965-1992. Ann Intern Med 1997, 126:433-440.
8. Wermers R.A., Khosla S., Atkinson E.J., et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006, 21:171-177.
9. Yeh M.W., Ituarte P.H., Zhou H.C., et al. Incidence and prevalence of primary hyperparathyroidism in a racially mixed population. J Clin Endocrinol Metab 2013, 98:1122-1129.
10. St Sauver J.L., Grossardt B.R., Yawn B.P., et al. Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system. Int J Epidemiol 2012, 41:1614-1624.
11. Rocca W.A., Yawn B.P., St Sauver J.L., Grossardt B.R., Melton L.J. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc 2012, 87:1202-1213.
12. St Sauver J.L., Grossardt B.R., Yawn B.P., Melton L.J., Rocca W.A. Use of a medical records linkage system to enumerate a dynamic population over time: the Rochester epidemiology project. Am J Epidemiol 2011, 173:1059-1068.
13. Stafford R.S., Drieling R.L., Hersh A.L. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. Arch Intern Med 2004, 164:1525-1530.
14. Tannenbaum C., Clark J., Schwartzman K., et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab 2002, 87:4431-4437.
15. National Osteoporosis Foundation Physician's guide to prevention and treatment of osteoporosis 1998, 1-29. (Washington, DC).
16. Jaglal S.B., McIsaac W.J., Hawker G., Jaakkimainen L., Cadarette S.M., Chan B.T. Patterns of use of the bone mineral density test in Ontario, 1992-1998. CMAJ 2000, 163:1139-1143.
17. Farley J.F., Blalock S.J. Trends and determinants of prescription medication use for treatment of osteoporosis. Am J Health Syst Pharm 2009, 66:1191-1201.
18. Marcus R., Madvig P., Crim M., Pont A., Kosek J. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984, 100:633-640.
19. Hersh A.L., Stefanick M.L., Stafford R.S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004, 291:47-53.
20. Haas J.S., Kaplan C.P., Gerstenberger E.P., Kerlikowske K. Changes in the use of postmenopausal hormone therapy after the publication of clinical trial results. Ann Intern Med 2004, 140:184-188.
21. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
22. Bolland M.J., Grey A.B., Gamble G.D., Reid I.R. Association between primary hyperparathyroidism and increased body weight: a meta-analysis. J Clin Endocrinol Metab 2005, 90:1525-1530.
23. Khosla S., Ebeling P.R., Firek A.F., Burritt M.M., Kao P.C., Heath H. Calcium infusion suggests a "set-point" abnormality of parathyroid gland function in familial benign hypercalcemia and more complex disturbances in primary hyperparathyroidism. J Clin Endocrinol Metab 1993, 76:715-720.
24. Insogna K.L., Mitnick M.E., Stewart A.F., Burtis W.J., Mallette L.E., Broadus A.E. Sensitivity of the parathyroid hormone-1,25-dihydroxyvitamin D axis to variations in calcium intake in patients with primary hyperparathyroidism. N Engl J Med 1985, 313:1126-1130.
25. Tohme J.F., Bilezikian J.P., Clemens T.L., Silverberg S.J., Shane E., Lindsay R. Suppression of parathyroid hormone secretion with oral calcium in normal subjects and patients with primary hyperparathyroidism. J Clin Endocrinol Metab 1990, 70:951-956.
26. Rao D.S., Honasoge M., Divine G.W., et al. Effect of vitamin D nutrition on parathyroid adenoma weight: pathogenetic and clinical implications. J Clin Endocrinol Metab 2000, 85:1054-1058.
27. Grey A., Lucas J., Horne A., Gamble G., Davidson J.S., Reid I.R. Vitamin D repletion in patients with primary hyperparathyroidism and coexistent vitamin D insufficiency. J Clin Endocrinol Metab 2005, 90:2122-2126.
28. Paik J.M., Curhan G.C., Taylor E.N. Calcium intake and risk of primary hyperparathyroidism in women: prospective cohort study. BMJ 2012, 345:e6390.
29. Mangano K.M., Walsh S.J., Insogna K.L., Kenny A.M., Kerstetter J.E. Calcium intake in the United States from dietary and supplemental sources across adult age groups: new estimates from the National Health and Nutrition Examination Survey 2003-2006. J Am Diet Assoc 2011, 111:687-695.
30. Bailey R.L., Dodd K.W., Goldman J.A., et al. Estimation of total usual calcium and vitamin D intakes in the United States. J Nutr 2010, 140:817-822.
31. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006, 295:2164-2167.
32. Leenhardt L., Bernier M.O., Boin-Pineau M.H., et al. Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol 2004, 150:133-139.
33. Bilezikian J.P., Potts J.T., Fuleihan Gel H., et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Miner Res 2002, 17(Suppl. 2):N2-N11.
34. Yoo J.W., Nakagawa S., Kim S. Effect of reimbursement reductions on bone mineral density testing for female Medicare beneficiaries. J Womens Health (Larchmt) 2012, 21:1144-1148.